The U.S. Meals and Drug Administration has authorized the single-dose Ajovy (fremanezumab-vfrm) injection for the preventive therapy of episodic migraine in youngsters and adolescents.
In the US, one in 10 youngsters and adolescents expertise migraine, a typical however typically underrecognized and undertreated situation that may trigger missed college, tutorial challenges, and social disruptions.
Ajovy is the primary and solely calcitonin gene-related peptide antagonist authorized for pediatric episodic migraine prevention and migraine prevention in adults. Ajovy is permitted for adults and youngsters/adolescents aged 6 to 17 years and weighing at the very least 45 kg (99 lb). Ajovy is a 225-mg/1.5-mL single-dose injection, obtainable in a prefilled autoinjector or syringe, and will be given by a well being care skilled or self-administered or administered by a father or mother or caregiver within the house surroundings.
“Pediatric migraine is a complex condition that can significantly impact a child’s daily life, from school performance to emotional well-being,” Jennifer McVige, M.D., from the DENT Neurologic Institute in Buffalo, New York, mentioned in a press release. “Having an FDA-approved treatment like Ajovy offers an important option, providing a targeted approach to preventive treatment for episodic migraine that can help reduce the frequency of attacks in younger patients and help clinicians manage this often-overlooked condition.”
Approval of Ajovy was granted to Teva Prescribed drugs.
Extra data:
Extra Data
Quotation:
Fda approves Ajovy for migraine prevention in youngsters and youths (2025, August 11)
retrieved 11 August 2025
from https://medicalxpress.com/information/2025-08-fda-ajovy-migraine-children-teens.html
This doc is topic to copyright. Aside from any honest dealing for the aim of personal research or analysis, no
half could also be reproduced with out the written permission. The content material is offered for data functions solely.
